Publications by authors named "Mark Midei"

Claim this Profile
A
A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
Daphne N Weemering, Mark Midei, Peter Milner, Vidhya Gopalakrishnan, Anil Kumar

Eur J Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.
David R Lynch, Katherine D Mathews, Susan Perlman, Theresa Zesiewicz, Sub Subramony, Mark Midei

J Neurol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.
Megan Yerton, Allison Winter, Anthony Kostov, Cassandra Lieberman, Dario Gelevski, Mark G Midei

Muscle Nerve· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrophysiological and ECG Effects of Perhexiline, a Mixed Cardiac Ion Channel Inhibitor, Evaluated in Nonclinical Assays and in Healthy Subjects.
Mark G Midei, Borje Darpo, Greg Ayers, Randy Brown, Jean-Philippe Couderc

J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RT001 in Progressive Supranuclear Palsy-Clinical and In-Vitro Observations.
Plamena R Angelova, Kristin M Andruska, Mark G Midei, Mario Barilani, Paldeep Atwal

Antioxidants (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma and Red Blood Cell Membrane Accretion and Pharmacokinetics of RT001 (bis-Allylic 11,11-D2-Linoleic Acid Ethyl Ester) during Long Term Dosing in Patients.
J Thomas Brenna, Genevieve James, Mark Midei, Frederic Heerinckx, Paldeep Atwal

J Pharm Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of infantile neuroaxonal dystrophy with RT001: A di-deuterated ethyl ester of linoleic acid: Report of two cases.
Darius Adams, Mark Midei, Jahannaz Dastgir, Christina Flora, Robert J Molinari

JIMD Rep· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The infantile neuroaxonal dystrophy rating scale (INAD-RS).
Paldeep S Atwal, Mark Midei, Darius Adams, Alexander Fay, Frederic Heerinckx

Orphanet J Rare Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The natural history of infantile neuroaxonal dystrophy.
Fadie D Altuame, Gretchen Foskett, Paldeep S Atwal, Sarah Endemann, Mark Midei

Orphanet J Rare Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Only 20-25% Deuteration of Polyunsaturated Fatty Acids Prevents Lipid Peroxidation.
Paldeep S Atwal, Mark Midei, Peter Milner

Trends Mol Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
Detlef Albrecht, Mintu P Turakhia, Daniel Ries, Thomas Marbury, William Smith, Mark G Midei

Thromb Haemost· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The validation of an LC-MS/MS assay for perhexiline and major hydroxy metabolites, and its application to therapeutic monitoring in patient plasma.
Patrick Camilleri, Duxi Zhang, Mark Midei, William Daly, James Copp

Bioanalysis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
Detlef Albrecht, David Ellis, Daniel M Canafax, Daniel Combs, Pascal Druzgala, Mark G Midei

Thromb Haemost· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Richard P Whitlock, Christopher B Fordyce, Mark G Midei, Dave Ellis, David Garcia

Thromb Haemost· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial.
William A Gray, Alan C Yeung, Donald E Cutlip, Jeffrey J Popma, Peter J Fitzgerald, Mark G Midei

Int J Cardiol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
Gregg W Stone, Sheldon Goldberg, Charles O'Shaughnessy, Mark Midei, Robert M Siegel

JACC Cardiovasc Interv· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
Alexandra J Lansky, Vivian G Ng, Halil Mutlu, Ecaterina Cristea, Julian Benetato Guiran, Mark Midei

Catheter Cardiovasc Interv· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Gregg W Stone, Mark Midei, William Newman, Mark Sanz, James B Hermiller

Circulation· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
Gregg W Stone, Mark Midei, William Newman, Mark Sanz, James B Hermiller

JAMA· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
Mark G Midei, Vicki J Coombs, David R Lowry, Michael N Drossner, Kerry C Prewitt

Cardiology· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
David E Kandzari, Martin B Leon, Jeffrey J Popma, Peter J Fitzgerald, Charles O'Shaughnessy, Mark G Midei

J Am Coll Cardiol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease.
Alexandra J Lansky, Ricardo A Costa, Michael Mooney, Mark G Midei, Henry K Lui

J Am Coll Cardiol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
Victor L Serebruany, Mark G Midei, Alex I Malinin, Benjamin R Oshrine, David R Lowry

Arch Intern Med· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial.
Alexandra J Lansky, Ricardo A Costa, Gary S Mintz, Yoshihiro Tsuchiya, Mark Midei

Circulation· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.
David R Holmes, Martin B Leon, Jeffrey W Moses, Jeffrey J Popma, Donald Cutlip, Mark Midei

Circulation· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis